Caris Life Sciences (CAI) Return on Capital Employed (2025 - 2026)

Caris Life Sciences (CAI) posted quarterly Return on Capital Employed of 10.83% for Q1 2026, up 122.84% quarter-over-quarter from 4.86% in Q4 2025.

Caris Life Sciences (CAI) Return on Capital Employed (2025 - 2026) Analysis & Trends

Caris Life Sciences' Return on Capital Employed history runs 2 years deep, the most recent figure standing at 10.83% for Q1 2026.

In Q1 2026, Return on Capital Employed changed N/A year-over-year to 10.83%; the TTM figure through Mar 2026 stood at 10.83% (changed N/A YoY), while the FY2025 annual figure was 7.43%, changed N/A from the prior year.
Return on Capital Employed for Q1 2026 stood at 10.83%, up from 4.86% in the prior quarter.
The five-year high for Return on Capital Employed was 10.83% in Q1 2026, with the low at 9.09% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	10.74%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-55.45%
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	7.88%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	26.09%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-50.93%
10	Caris Life Sciences	6.16 Bn	5.37 Bn	182.38 Mn	15.26%

Download Data